Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 3,181 - 3,200 results of 18,518 for search 'significantly ((((((larger decrease) OR (a decrease))) OR (greater decrease))) OR (mean decrease))', query time: 0.47s Refine Results
  1. 3181
    IFA reduced the capsular biosynthesis through altering bacterial metabolism.

    IFA reduced the capsular biosynthesis through altering bacterial metabolism. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  2. 3182
    IFA effectively reduced the production of <i>K</i>. <i>pneumoniae</i> capsule.

    IFA effectively reduced the production of <i>K</i>. <i>pneumoniae</i> capsule. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  3. 3183
    IFA reduced the virulence of hypervirulent <i>K</i>. <i>pneumoniae</i> in <i>G</i>. <i>mellonella</i> larvae.

    IFA reduced the virulence of hypervirulent <i>K</i>. <i>pneumoniae</i> in <i>G</i>. <i>mellonella</i> larvae. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  4. 3184
    IFA did not affect LPS-induced inflammation response.

    IFA did not affect LPS-induced inflammation response. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  5. 3185
    IFA abrogated capsule-associated hypermucoviscosity phenotypes of hypervirulent <i>K</i>. <i>pneumoniae</i>.

    IFA abrogated capsule-associated hypermucoviscosity phenotypes of hypervirulent <i>K</i>. <i>pneumoniae</i>. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  6. 3186
    IFA sensitized hypervirulent <i>K</i>. <i>pneumoniae</i> to complement-mediated killing by inhibiting capsule.

    IFA sensitized hypervirulent <i>K</i>. <i>pneumoniae</i> to complement-mediated killing by inhibiting capsule. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  7. 3187
    IFA treatment facilitated host immune clearance of hypervirulent <i>K</i>. <i>pneumoniae</i> by targeting capsule.

    IFA treatment facilitated host immune clearance of hypervirulent <i>K</i>. <i>pneumoniae</i> by targeting capsule. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  8. 3188
    IFA effectively limited bacterial dissemination and protected mice from lethal hypervirulent <i>K</i>. <i>pneumoniae</i> pneumonia.

    IFA effectively limited bacterial dissemination and protected mice from lethal hypervirulent <i>K</i>. <i>pneumoniae</i> pneumonia. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  9. 3189
    Safranin O fast green staining results of cartilage tissue in different groups of rat PTOA (A: normal group, B: mild PTOA group, C: severe PTOA group).

    Safranin O fast green staining results of cartilage tissue in different groups of rat PTOA (A: normal group, B: mild PTOA group, C: severe PTOA group). by Peng-fei Han (694841)

    Published 2025
    Save to List
    Saved in:
  10. 3190
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  11. 3191
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  12. 3192
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  13. 3193
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  14. 3194
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  15. 3195
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  16. 3196
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  17. 3197
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  18. 3198
    Image 4_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff

    Image 4_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff by Priscila Silva (556743)

    Published 2025
    “…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
    Save to List
    Saved in:
  19. 3199
    Image 2_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff

    Image 2_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff by Priscila Silva (556743)

    Published 2025
    “…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
    Save to List
    Saved in:
  20. 3200
    Image 1_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tif

    Image 1_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tif by Priscila Silva (556743)

    Published 2025
    “…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
    Save to List
    Saved in:

Search Tools: